Designing siRNA that distinguish between genes that differ by a single nucleotide
- PMID: 16965178
- PMCID: PMC1560399
- DOI: 10.1371/journal.pgen.0020140
Designing siRNA that distinguish between genes that differ by a single nucleotide
Abstract
Small interfering RNAs (siRNAs), the guides that direct RNA interference (RNAi), provide a powerful tool to reduce the expression of a single gene in human cells. Ideally, dominant, gain-of-function human diseases could be treated using siRNAs that specifically silence the mutant disease allele, while leaving expression of the wild-type allele unperturbed. Previous reports suggest that siRNAs can be designed with single nucleotide specificity, but no rational basis for the design of siRNAs with single nucleotide discrimination has been proposed. We systematically identified siRNAs that discriminate between the wild-type and mutant alleles of two disease genes: the human Cu, Zn superoxide dismutase (SOD1) gene, which contributes to the progression of hereditary amyotrophic lateral sclerosis through the gain of a toxic property, and the huntingtin (HTT) gene, which causes Huntington disease when its CAG-repeat region expands beyond approximately 35 repeats. Using cell-free RNAi reactions in Drosophila embryo lysate and reporter assays and microarray analysis of off-target effects in cultured human cells, we identified positions within an siRNA that are most sensitive to mismatches. We also show that purine:purine mismatches imbue an siRNA with greater discriminatory power than other types of base mismatches. siRNAs in which either a G:U wobble or a mismatch is located in the "seed" sequence, the specialized siRNA guide region responsible for target binding, displayed lower levels of selectivity than those in which the mismatch was located 3' to the seed; this region of an siRNA is critical for target cleavage but not siRNA binding. Our data suggest that siRNAs can be designed to discriminate between the wild-type and mutant alleles of many genes that differ by just a single nucleotide.
Conflict of interest statement
Competing interests. PDZ is a co-founder and advisor for Alnylam Pharmaceuticals, Inc., an siRNA therapeutics company.
Figures
Similar articles
-
Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.Chin Med J (Engl). 2011 Jan;124(1):106-10. Chin Med J (Engl). 2011. PMID: 21362317
-
Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele.Acta Pharmacol Sin. 2008 Feb;29(2):211-6. doi: 10.1111/j.1745-7254.2008.00740.x. Acta Pharmacol Sin. 2008. PMID: 18215350
-
Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi.PLoS One. 2008 May 21;3(5):e2248. doi: 10.1371/journal.pone.0002248. PLoS One. 2008. PMID: 18493311 Free PMC article.
-
Short interfering RNA (siRNA) as a novel therapeutic.Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):504-10. doi: 10.1111/j.1440-1681.2006.04399.x. Clin Exp Pharmacol Physiol. 2006. Retraction in: Clin Exp Pharmacol Physiol. 2013 Apr;40(4):305. doi: 10.1111/1440-1681.12073 Retraction in: Clin Exp Pharmacol Physiol. 2013 Apr;40(4):305. doi: 10.1111/1440-1681.12075 PMID: 16700886 Retracted. Review.
-
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.RNA. 2007 Apr;13(4):431-56. doi: 10.1261/rna.459807. Epub 2007 Feb 28. RNA. 2007. PMID: 17329355 Free PMC article. Review.
Cited by
-
siRNAs with decreased off-target effect facilitate the identification of essential genes in cancer cells.Oncotarget. 2015 Aug 28;6(25):21603-13. doi: 10.18632/oncotarget.4269. Oncotarget. 2015. PMID: 26057633 Free PMC article.
-
Antisense oligonucleotides: a novel Frontier in pharmacological strategy.Front Pharmacol. 2023 Nov 17;14:1304342. doi: 10.3389/fphar.2023.1304342. eCollection 2023. Front Pharmacol. 2023. PMID: 38044945 Free PMC article. Review.
-
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.Nature. 2015 May 21;521(7552):362-5. doi: 10.1038/nature14442. Epub 2015 Apr 22. Nature. 2015. PMID: 25901685 Free PMC article.
-
RNAi therapeutics: a potential new class of pharmaceutical drugs.Nat Chem Biol. 2006 Dec;2(12):711-9. doi: 10.1038/nchembio839. Nat Chem Biol. 2006. PMID: 17108989 Free PMC article. Review.
-
Large scale analysis of positional effects of single-base mismatches on microarray gene expression data.BioData Min. 2010 Apr 29;3(1):2. doi: 10.1186/1756-0381-3-2. BioData Min. 2010. PMID: 20429935 Free PMC article.
References
-
- Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000;404:293–296. - PubMed
-
- Martinez J, Patkaniowska A, H HU, Lührmann R, Tuschl T. Single stranded antisense siRNA guide target RNA cleavage in RNAi. Cell. 2002;110:563–574. - PubMed
-
- Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell. 2001;107:309–321. - PubMed
-
- Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498. - PubMed
-
- Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006;439:89–94. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous